| 000 | 01573 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518003418.0 | ||
| 264 | 0 | _c20190813 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1759-7714 | ||
| 024 | 7 |
_a10.1111/1759-7714.12898 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Di | |
| 245 | 0 | 0 |
_aClinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study. _h[electronic resource] |
| 260 |
_bThoracic cancer _c12 2018 |
||
| 300 |
_a1754-1762 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aBiomarkers, Tumor |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aZhang, Chufeng | |
| 700 | 1 | _aHuang, Jiaqi | |
| 700 | 1 | _aGuan, Yan | |
| 700 | 1 | _aGuo, Qisen | |
| 773 | 0 |
_tThoracic cancer _gvol. 9 _gno. 12 _gp. 1754-1762 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/1759-7714.12898 _zAvailable from publisher's website |
| 999 |
_c28956550 _d28956550 |
||